Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice

Journal of Immunology

Volumn 192, Issue 11, 2014, Pages 5324-5331

  Huber Lang, Markus ^a   Barratt Due, Andreas ^b,c   Pischke, Søren E ^b   Sandanger, Øystein ^d   Nilsson, Per H ^b   Nunn, Miles A ^e   Denk, Stephanie ^a   Gaus, Wilhelm ^a   Espevik, Terje ^f   Mollnes, Tom E ^b,f,g  

^a UNIVERSITY OF ULM   (Germany)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e CENTRE FOR ECOLOGY AND HYDROLOGY   (United Kingdom)

^f NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^g UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BIG 53; CD14 ANTIBODY; CD14 ANTIGEN; CHEMOKINE; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5 INHIBITOR; COVERSIN; CXCL1 CHEMOKINE; CYTOKINE; GROWTH FACTOR; IMMUNOGLOBULIN F(AB')2 FRAGMENT; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE STORM; DRUG MECHANISM; EXPERIMENTAL INFECTION; EYELID MOVEMENT; IMMUNOREGULATION; INFLAMMATORY DISEASE; LEUKOCYTE ACTIVATION; MALE; MORTALITY; MOUSE; NONHUMAN; POLYMICROBIAL SEPSIS; PRIORITY JOURNAL; RECEPTOR BLOCKING; SEPSIS; SINGLE DRUG DOSE; SURVIVAL; SURVIVAL TIME; SYSTEMIC DISEASE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD14; COMPLEMENT C5; CYTOKINES; MALE; MICE; SEPSIS; TIME FACTORS;

EID: 84901274991     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400341     Document Type: Article

References (65)

1. Kumar, G., N. Kumar, A. Taneja, T. Kaleekal, S. Tarima, E. McGinley, E. Jimenez, A. Mohan, R. A. Khan, J. Whittle, et al; Milwaukee Initiative in Critical Care Outcomes Research Group of Investigators. 2011. Nationwide trends of severe sepsis in the 21st century (2000-2007). Chest 140: 1223-1231.
2. Rivers, E., B. Nguyen, S. Havstad, J. Ressler, A. Muzzin, B. Knoblich, E. Peterson, and M. Tomlanovich; Early Goal-Directed Therapy Collaborative Group. 2001. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 345: 1368-1377.
3. Angus, D. C., and T. van der Poll. 2013. Severe sepsis and septic shock. N. Engl. J. Med. 369: 840-851.
4. Opal, S. M., P. F. Laterre, B. Francois, S. P. LaRosa, D. C. Angus, J. P. Mira, X. Wittebole, T. Dugernier, D. Perrotin, M. Tidswell, et al; ACCESS Study Group. 2013. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 309: 1154- 1162.
5. 2011. In brief: Xigris withdrawn. Med. Lett. Drugs Ther. 53: 104.
6. 2012. Focus on sepsis. Nat. Med. 18: 997.
7. Williams, S. C. 2012. After Xigris, researchers look to new targets to combat sepsis. Nat. Med. 18: 1001.
8. Khamsi, R. 2012. Execution of sepsis trials needs an overhaul, experts say. Nat. Med. 18: 998-999.
9. Moyer, M. W. 2012. New biomarkers sought for improving sepsis management and care. Nat. Med. 18: 999.
10. Mollnes, T. E., D. Christiansen, O. L. Brekke, and T. Espevik. 2008. Hypothesis: combined inhibition of complement and CD14 as treatment regimen to attenuate the inflammatory response. Adv. Exp. Med. Biol. 632: 253-263.
11. Barratt-Due, A., S. E. Pischke, O. L. Brekke, E. B. Thorgersen, E. W. Nielsen, T. Espevik, M. Huber-Lang, and T. E. Mollnes. 2012. Bride and groom in systemic inflammation - the bells ring for complement and Toll in cooperation. Immunobiology 217: 1047-1056.
12. Rittirsch, D., M. S. Huber-Lang,M. A. Flierl, and P. A.Ward. 2009. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat. Protoc. 4: 31-36.
13. Akashi-Takamura, S., and K. Miyake. 2008. TLR accessory molecules. Curr. Opin. Immunol. 20: 420-425.
14. Lloyd-Jones, K. L., M. M. Kelly, and P. Kubes. 2008. Varying importance of soluble and membrane CD14 in endothelial detection of lipopolysaccharide. J. Immunol. 181: 1446-1453.
15. Lee, C. C., A. M. Avalos, and H. L. Ploegh. 2012. Accessory molecules for Tolllike receptors and their function. Nat. Rev. Immunol. 12: 168-179.
16. Ricklin, D., G. Hajishengallis, K. Yang, and J. D. Lambris. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785- 797.
17. Brandtzaeg, P., T. E. Mollnes, and P. Kierulf. 1989. Complement activation and endotoxin levels in systemic meningococcal disease. J. Infect. Dis. 160: 58-65.
18. Ward, P. A. 2004. The dark side of C5a in sepsis. Nat. Rev. Immunol. 4: 133-142.
19. Ward, P. A. 2010. The harmful role of c5a on innate immunity in sepsis. J. Innate Immun. 2: 439-445.
20. Hajishengallis, G., and J. D. Lambris. 2010. Crosstalk pathways between Tolllike receptors and the complement system. Trends Immunol. 31: 154-163.
21. Song, W. C. 2012. Crosstalk between complement and toll-like receptors. Toxicol. Pathol. 40: 174-182.
22. Raby, A. C., B. Holst, J. Davies, C. Colmont, Y. Laumonnier, B. Coles, S. Shah, J. Hall, N. Topley, J. Köhl, et al. 2011. TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2. Eur. J. Immunol. 41: 2741-2752.
23. Holst, B., A. C. Raby, J. E. Hall, and M. O. Labéta. 2012. Complement takes its Toll: an inflammatory crosstalk between Toll-like receptors and the receptors for the complement anaphylatoxin C5a. Anaesthesia 67: 60-64.
24. Mollnes, T. E., O. L. Brekke, M. Fung, H. Fure, D. Christiansen, G. Bergseth, V. Videm, K. T. Lappegard, J. Köhl, and J. D. Lambris. 2002. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100: 1869-1877.
25. Brekke, O. L., D. Christiansen, H. Fure, M. Fung, and T. E. Mollnes. 2007. The role of complement C3 opsonization, C5a receptor, and CD14 in E. coli-induced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human whole blood. J. Leukoc. Biol. 81: 1404-1413.
26. Brekke, O. L., D. Christiansen, H. Fure, A. Pharo, M. Fung, J. Riesenfeld, and T. E. Mollnes. 2008. Combined inhibition of complement and CD14 abolish E. coli-induced cytokine-, chemokine- and growth factor-synthesis in human whole blood. Mol. Immunol. 45: 3804-3813.
27. Hellerud, B. C., J. Stenvik, T. Espevik, J. D. Lambris, T. E. Mollnes, and P. Brandtzaeg. 2008. Stages of meningococcal sepsis simulated in vitro, with emphasis on complement and Toll-like receptor activation. Infect. Immun. 76: 4183-4189.
28. Lappegard, K. T., D. Christiansen, A. Pharo, E. B. Thorgersen, B. C. Hellerud, J. Lindstad, E. W. Nielsen, G. Bergseth, D. Fadnes, T. G. Abrahamsen, et al. 2009. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc. Natl. Acad. Sci. USA 106: 15861-15866.
29. Barratt-Due, A., E. B. Thorgersen, K. Egge, S. Pischke, A. Sokolov, B. C. Hellerud, J. K. Lindstad, A. Pharo, A. K. Bongoni, R. Rieben, et al. 2013. Combined inhibition of complement C5 and CD14 markedly attenuates inflammation, thrombogenicity, and hemodynamic changes in porcine sepsis. J. Immunol. 191: 819-827.
30. Nunn, M. A., A. Sharma, G. C. Paesen, S. Adamson, O. Lissina, A. C. Willis, and P. A. Nuttall. 2005. Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata. J. Immunol. 174: 2084-2091.
31. Dejager, L., I. Pinheiro, E. Dejonckheere, and C. Libert. 2011. Cecal ligation and puncture: the gold standard model for polymicrobial sepsis? Trends Microbiol. 19: 198-208.
32. Barratt-Due, A., E. B. Thorgersen, J. K. Lindstad, A. Pharo, O. L. Brekke, D. Christiansen, J. D. Lambris, and T. E. Mollnes. 2010. Selective inhibition of TNF-alpha or IL-1 beta does not affect E. coli-induced inflammation in human whole blood. Mol. Immunol. 47: 1774-1782.
33. Remick, D. G. 2007. Pathophysiology of sepsis. Am. J. Pathol. 170: 1435-1444.
34. Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124: 783-801.
35. Takeuchi, O., and S. Akira. 2010. Pattern recognition receptors and inflammation. Cell 140: 805-820.
36. Sarma, J. V., and P. A. Ward. 2011. The complement system. Cell Tissue Res. 343: 227-235.
37. Rossol, M., H. Heine, U. Meusch, D. Quandt, C. Klein, M. J. Sweet, and S. Hauschildt. 2011. LPS-induced cytokine production in human monocytes and macrophages. Crit. Rev. Immunol. 31: 379-446.
38. Clark, S. R., A. C. Ma, S. A. Tavener, B. McDonald, Z. Goodarzi, M. M. Kelly, K. D. Patel, S. Chakrabarti, E. McAvoy, G. D. Sinclair, et al. 2007. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat. Med. 13: 463-469.
39. Haziot, A., E. Ferrero, F. Köntgen, N. Hijiya, S. Yamamoto, J. Silver, C. L. Stewart, and S. M. Goyert. 1996. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 4: 407-414.
40. Leturcq, D. J., A. M. Moriarty, G. Talbott, R. K. Winn, T. R. Martin, and R. J. Ulevitch. 1996. Antibodies against CD14 protect primates from endotoxininduced shock. J. Clin. Invest. 98: 1533-1538.
41. Schimke, J., J. Mathison, J. Morgiewicz, and R. J. Ulevitch. 1998. Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc. Natl. Acad. Sci. USA 95: 13875-13880.
42. Ferrero, E., D. Jiao, B. Z. Tsuberi, L. Tesio, G. W. Rong, A. Haziot, and S. M. Goyert. 1993. Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide. Proc. Natl. Acad. Sci. USA 90: 2380-2384.
43. Verbon, A., P. E. Dekkers, T. ten Hove, C. E. Hack, J. P. Pribble, T. Turner, S. Souza, T. Axtelle, F. J. Hoek, S. J. van Deventer, and T. van der Poll. 2001. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J. Immunol. 166: 3599-3605.
44. Thorgersen, E. B., B. C. Hellerud, E. W. Nielsen, A. Barratt-Due, H. Fure, J. K. Lindstad, A. Pharo, E. Fosse, T. I. Tønnessen, H. T. Johansen, et al. 2010. CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs. FASEB J. 24: 712-722.
45. Ebong, S. J., S. M. Goyert, J. A. Nemzek, J. Kim, G. L. Bolgos, and D. G. Remick. 2001. Critical role of CD14 for production of proinflammatory cytokines and cytokine inhibitors during sepsis with failure to alter morbidity or mortality. Infect. Immun. 69: 2099-2106.
46. Hyde, S. R., R. D. Stith, and R. E. McCallum. 1990. Mortality and bacteriology of sepsis following cecal ligation and puncture in aged mice. Infect. Immun. 58: 619-624.
47. Gangloff, S. C., N. Hijiya, A. Haziot, and S. M. Goyert. 1999. Lipopolysaccharide structure influences the macrophage response via CD14-independent and CD14-dependent pathways. Clin. Infect. Dis. 28: 491-496.
48. Huber-Lang, M., J. V. Sarma, F. S. Zetoune, D. Rittirsch, T. A. Neff, S. R. McGuire, J. D. Lambris, R. L. Warner, M. A. Flierl, L. M. Hoesel, et al. 2006. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12: 682-687.
49. Markiewski, M. M., B. Nilsson, K. N. Ekdahl, T. E. Mollnes, and J. D. Lambris. 2007. Complement and coagulation: strangers or partners in crime? Trends Immunol. 28: 184-192.
50. Unnewehr, H., D. Rittirsch, J. V. Sarma, F. Zetoune, M. A. Flierl, M. Perl, S. Denk, M. Weiss, M. E. Schneider, P. N. Monk, et al. 2013. Changes and regulation of the C5a receptor on neutrophils during septic shock in humans. J. Immunol. 190: 4215-4225.
51. Huber-Lang, M., V. J. Sarma, K. T. Lu, S. R. McGuire, V. A. Padgaonkar, R. F. Guo, E. M. Younkin, R. G. Kunkel, J. Ding, R. Erickson, et al. 2001. Role of C5a in multiorgan failure during sepsis. J. Immunol. 166: 1193-1199.
52. Silasi-Mansat, R., H. Zhu, N. I. Popescu, G. Peer, G. Sfyroera, P. Magotti, L. Ivanciu, C. Lupu, T. E. Mollnes, F. B. Taylor, et al. 2010. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 116: 1002-1010.
53. Rother, R. P., S. A. Rollins, C. F. Mojcik, R. A. Brodsky, and L. Bell. 2007. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 25: 1256- 1264.
54. Barratt-Due, A., E. B. Thorgersen, J. K. Lindstad, A. Pharo, O. Lissina, J. D. Lambris, M. A. Nunn, and T. E. Mollnes. 2011. Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans. J. Immunol. 187: 4913-4919.
55. Thorgersen, E. B., S. E. Pischke, A. Barratt-Due, H. Fure, J. K. Lindstad, A. Pharo, B. C. Hellerud, and T. E. Mollnes. 2013. Systemic CD14 inhibition attenuates organ inflammation in porcine Escherichia coli sepsis. Infect. Immun. 81: 3173-3181.
56. Kaczorowski, D. J., A. Afrazi, M. J. Scott, J. H. Kwak, R. Gill, R. D. Edmonds, Y. Liu, J. Fan, and T. R. Billiar. 2010. Pivotal advance: The pattern recognition receptor ligands lipopolysaccharide and polyinosine-polycytidylic acid stimulate factor B synthesis by the macrophage through distinct but overlapping mechanisms. J. Leukoc. Biol. 88: 609-618.
57. Zhang, X., Y. Kimura, C. Fang, L. Zhou, G. Sfyroera, J. D. Lambris, R. A. Wetsel, T. Miwa, and W. C. Song. 2007. Regulation of Toll-like receptormediated inflammatory response by complement in vivo. Blood 110: 228-236.
58. Riedemann, N. C., T. A. Neff, R. F. Guo, K. D. Bernacki, I. J. Laudes, J. V. Sarma, J. D. Lambris, and P. A. Ward. 2003. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J. Immunol. 170: 503-507.
59. Panacek, E. A., J. C. Marshall, T. E. Albertson, D. H. Johnson, S. Johnson, R. D. MacArthur, M. Miller, W. T. Barchuk, S. Fischkoff, M. Kaul, et al; Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators. 2004. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit. Care Med. 32: 2173-2182.
60. Remick, D. G., G. Bolgos, S. Copeland, and J. Siddiqui. 2005. Role of interleukin-6 in mortality from and physiologic response to sepsis. Infect. Immun. 73: 2751-2757.
61. Egge, K. H., E. B. Thorgersen, J. K. Lindstad, A. Pharo, J. D. Lambris, A. Barratt-Due, and T. E. Mollnes. 2014. Post challenge inhibition of C3 and CD14 attenuates Escherichia coli-induced inflammation in human whole blood. Innate Immun. 20: 68-77.
62. Xiao, W., M. N. Mindrinos, J. Seok, J. Cuschieri, A. G. Cuenca, H. Gao, D. L. Hayden, L. Hennessy, E. E. Moore, J. P. Minei, et al; Inflammation and Host Response to Injury Large-Scale Collaborative Research Program. 2011. A genomic storm in critically injured humans. J. Exp. Med. 208: 2581-2590.
63. Mutlak, H., C. Jennewein, N. Tran, M. Mehring, K. Latsch, K. Habeck, P. A. Ockelmann, B. Scheller, K. Zacharowski, and P. Paulus. 2013. Cecum ligation and dissection: a novel modified mouse sepsis model. J. Surg. Res. 183: 321-329.
64. Ricklin, D., and J. D. Lambris. 2013. Complement in immune and inflammatory disorders: therapeutic interventions. J. Immunol. 190: 3839-3847.
65. Lau, C., K. S. Gunnarsen, L. S. Høydahl, J. T. Andersen, G. Berntzen, A. Pharo, J. K. Lindstad, J. K. Ludviksen, O. L. Brekke, A. Barratt-Due, et al. 2013. Chimeric anti-CD14 IGG2/4 Hybrid antibodies for therapeutic intervention in pig and human models of inflammation. J. Immunol. 191: 4769-4777.